ANCA status (MPO-ANCA+ versus PR3-ANCA+), did not change these results. Despite similar immunosuppressive therapy approaches and relapse rates, elderly patients had a higher rate of severe infections compared to younger patients (OR 2.1, 95% CIs: 1.1-4.4, $p=0.043$; Figure below).

Abstract THU0290 – Figure 1

Conclusion: Our findings indicate that elderly patients had higher susceptibility to morbidity related to vasculitis or its treatment than younger patients, particularly to worst renal function recovery and higher infection rate.

REFERENCES:

- [1] Harper L, et al. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. *Rheumatology (Oxford, England)*. 2005;44(4):495-501.
- [2] Pagnoux C, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. *Arthritis & rheumatology (Hoboken, NJ)*. 2015;67(4):1117-27.
- [3] Yates M, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Annals of the rheumatic diseases*. 2016;75(9):1583-94.

Disclosure of Interests: Alvise Berti: None declared, Mara Felicetti: None declared, Sara Monti: None declared, Augusta Ortolan: None declared, Roberto Padoan: None declared, Giuliano Brunori: None declared, Roberto Bortolotti: None declared, Roberto Caporali Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Roche, Genzyme, Lilly, MSD, Pfizer, UCB, Carlomaurizio Montecucco Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Sanofi, Genzyme, Lilly, MSD, Pfizer, UCB, Franco Schiavon: None declared, Giuseppe Paolazzi: None declared

DOI: 10.1136/annrheumdis-2019-eular.6078

THU0291 THE CHARACTERISTICS OF PEDIATRIC BEHÇET'S DISEASE IN TURKEY VERSUS ISRAEL

Yonatan Butbul¹, Ezgi Deniz Batu², Hafize Emine Sonmez², Betül Sözeri³, Nuray Aktay Ayaz⁴, Limor Baba¹, Gil Amarilio⁵, Seval Simsek³, Liora Harel⁵, Şerife Gül Karadağ⁴, Yelda Bilginer², Seza Özen². ¹Ruth Rappaport Children's Hospital, Rambam Medical Center, Department of Pediatrics, Division of Rheumatology, Haifa, Israel; ²Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Rheumatology, Ankara, Turkey; ³Umraniye Training and Research Center, University of Health Sciences, Department of Pediatrics, Division of Rheumatology, Istanbul, Turkey; ⁴Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Department of Pediatrics, Division of Rheumatology, Istanbul, Turkey; ⁵Schneider Children's Medical Center of Israel, Department of Pediatrics, Division of Rheumatology, Petach Tikva, Israel

Background: Behçet's disease (BD) is a variable vessel vasculitis affecting all sizes of vasculature in both the arterial and venous systems. Children with BD comprises 3-24% of all BD patients.

Objectives: To compare the demographics, presentation, clinical manifestations, disease activity, and treatment in pediatric Behçet's disease in Turkey versus Israel.

Methods: Three centers from Turkey and two centers from Israel participated in this study. The diagnosis of BD was before 16 years of age and based on expert opinion at each center. BD current activity form (BDCAF) was used for assessing disease activity.

Results: A total of 205 patients were included (165 from Turkey; 40 from Israel). HLA-B51 positivity (68.3% vs 46.2%, $p=0.028$), male gender (52.1% vs 30%, $p=0.012$), and skin involvement (especially necrotic

folliculitis) (55.2% vs 22.5%, $p<0.001$) were more frequent among patients from Turkey compared to the ones from Israel. The first disease-related symptom was oral aphthosis in both groups followed by genital aphthosis and arthralgia/arthritis in patients from Turkey and Israel, respectively. The median BDCAF values were worse at the first visit for patients from Turkey than those from Israel (4 vs 2, $p<0.001$). The most commonly prescribed drug was colchicine in the whole group (96.6%). Significantly more patients were treated with corticosteroids (50% vs 28.5%, $p=0.006$), methotrexate (17.5% vs 3%, $p=0.002$), infliximab (10% vs 1.8%, $p=0.026$), and nonsteroidal anti-inflammatory drugs (12.5% vs 1.8%, $p=0.007$) in Israel than Turkey. For the classification of BD in the whole group, ICBD criteria had the highest sensitivity (73.2%) followed by PED-BD (pediatric BD) (47.8%) and ISG (The International Study Group) (42%) criteria sets.

Abstract THU291 – Table 1. The characteristics of children with Behçet's disease

Characteristics, n (%)	All patients (n=205)	Patients from Turkey (n=165)	Patients from Israel (n=40)	P value
Male	98 (47.8)	86 (52.1)	12 (30)	0.012
Age at symptom onset, months, median (min-max)	133 (12-191)	132 (12-191)	134 (12-190)	1
Age at diagnosis, months, median (min-max)	156 (48-191)	156 (48-191)	153 (55-191)	0.96
Oral aphthosis	204 (99.5)	165 (100)	39 (97.5)	0.195
Genital aphthosis	134 (65.4)	107 (64.8)	27 (67.5)	0.75
Skin involvement	100 (48.8)	91 (55.2)	9 (22.5)	<0.001
Eye involvement	29 (14.1)	22 (13.3)	7 (17.5)	0.49
Neurologic involvement	30 (14.6)	26 (15.8)	4 (10)	0.35
Vascular involvement	22 (10.7)	19 (11.5)	3 (7.5)	0.77
Pathergy positivity	45/167 (26.9)	42/154 (27.3)	3/13 (23.1)	1
HLA-B51 positivity	122/187 (65.2)	110/161 (68.3)	12/26 (46.2)	0.028
BDCAF at first visit	3 (0-15)	4 (1-15)	2 (0-5)	<0.001
BDCAF at last visit	1 (0-13)	1 (0-13)	1 (0-4)	0.15

Conclusion: This is the largest cohort of pediatric BD reported to date. The disease manifestations and disease activity significantly differ among pediatric BD patients from Turkey and Israel which emphasizes the effect of the ethnicity on disease phenotype.

REFERENCE:

- [1] Kone-Paut I, et al. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. *Ann Rheum Dis* 2016;75:958-64.

Disclosure of Interests: Yonatan Butbul: None declared, Ezgi Deniz Batu: None declared, Hafize Emine Sonmez: None declared, Betül Sözeri: None declared, Nuray Aktay Ayaz: None declared, Limor Baba: None declared, Gil Amarilio: None declared, Seval Simsek: None declared, Liora Harel: None declared, Şerife Gül Karadağ: None declared, Yelda Bilginer: None declared, Seza Özen Consultant for: Seza Ozen is receiving consultancy fees from Novartis, Speakers bureau: Roche

DOI: 10.1136/annrheumdis-2019-eular.2671

THU0292 EXTRACRANIAL VESSEL INVOLVEMENT IN PATIENTS WITH GIANT CELL ARTERITIS

Monica Calderón-Goercke¹, J. Loricera¹, D. Prieto-Peña¹, J. Narváez², Santos Castañeda³, Elena Aurrecoechea⁴, Ignacio Villa-Blanco⁴, Catalina Gomez-Arango⁵, Eva Perez-Pampin⁶, Vicente Aldasoro⁵, Noelia Alvarez-Rivas⁷, Nagore Fernández-Llanio⁸, María Álvarez del Buero⁹, Luisa Marena Rojas¹⁰, Francisca Sivera¹¹, Eva Galindez¹², Roser Solans-Laqué², Susana Romero-Yuste¹³, Norberto Ortego¹⁴, Marcelino Revenga³, Rafael Melero¹⁵, Eva Salgado-Pérez¹⁶, Sabela Fernández¹⁷, Vanesa Calvo-Río¹, Natalia Palmou-Fontana¹, Jose Ignacio Banzo¹, Isabel Martínez-Rodríguez¹, Carmen González-Vela¹, Raquel Dos-Santos⁵, J. Luis Hernández¹, Miguel A González-Gay¹, Ricardo Blanco¹. ¹Santander, Santander, Spain; ²Barcelona, Barcelona, Spain; ³Madrid, Madrid, Spain; ⁴Torrelavega, Torrelavega, Spain; ⁵Mondragón, Mondragón, Spain; ⁶Santiago, Santiago de Compostela, Spain; ⁷Lugo, Lugo, Spain; ⁸Lérida, Lérida, Spain; ⁹Palencia, Palencia, Spain; ¹⁰Alcázar San Juan, Alcázar de San Juan, Spain; ¹¹Alicante, Alicante, Spain; ¹²Bilbao, Bilbao, Spain; ¹³Pontevedra, Pontevedra, Spain; ¹⁴Granada, Granada, Spain; ¹⁵Vigo, Vigo, Spain; ¹⁶Ourense, Ourense, Spain; ¹⁷Avilés, Avilés, Spain

Background: Giant cell arteritis (GCA) is a large vessel vasculitis with a predisposition for the cranial branches of the external carotid artery. However, aorta and/or its main branches may also be involved.